PSA Testing in Point-of-Care Diagnostics: A Practical Guide
Prostate-specific antigen, commonly known as PSA, is one of the most frequently requested tumor markers in men’s health assessment. Because PSA measurement sits at the intersection of immunoassay science and everyday clinical decision-making, the way a testing platform performs — its sample requirements, turnaround time, and menu breadth — directly shapes how useful that measurement becomes. This guide examines how immunoassay-based PSA measurement fits into modern point-of-care testing, and how the capability system built by VivaChek Biotech (Hangzhou) Co., Ltd. supports that work.
What PSA Measurement Actually Involves
PSA is a protein produced by the epithelial cells of the prostate gland. Its concentration in blood can rise for several reasons, including benign prostate enlargement, inflammation of the prostate, and prostate cancer. For that reason, PSA is generally interpreted as one indicator among several rather than as a standalone diagnosis, and it is typically read alongside clinical examination and imaging.
Measuring PSA is an immunoassay task: the test relies on specific binding between antibodies and the target protein, then converts that binding event into a quantifiable signal. Laboratories have traditionally run such assays on large automated analyzers. The more recent shift is toward fluorescence immunochromatography, an assay format that supports quantitative immunoassay measurement in a compact instrument footprint — the same format used across the VivaChek immunofluorescence portfolio.
Why Point-of-Care Immunoassay Matters
Healthcare providers and patients increasingly need accessible health management, accurate point-of-care testing, and connected digital data sharing. Three practical pressures drive that shift:
- Sample burden. Immunoassay kits in the VivaChek range accept human whole blood from fingerstick or venous collection, serum, or plasma — a sample strategy that reduces the volume and processing steps required before a result is available.
- Time to answer. Professionals need rapid, reliable results to support quick decision-making. Fluorescence immunochromatography delivers results in just a few minutes from a tiny sample.
- Menu consolidation. Rather than maintaining separate platforms for separate markers, a single meter-and-kit system can address multiple parameters.
Inside the VivaChek Immunofluorescence Platform
The Instrument: VivaDiag Multifunction Meter (Model: VIM220H)
The VivaDiag Multifunction Meter works with VivaDiag FIA Test Kits as a system for the quantitative or qualitative measurement of multiple parameters. Its technical foundation is a photoelectric detection principle combined with fluorescence immunochromatography — the pairing that allows a small sample to yield a measurable signal within minutes. The system is intended for professional in vitro diagnostic use.
Reading the Menu: Where Tumor Markers Sit
VivaChek organizes its fluorescence immunoassay offering into defined product lines, among them Immunofluorescence——Instruments, Immunofluorescence——Cardiac markers, Immunofluorescence——Renal function, Immunofluorescence——Hormone, Immunofluorescence——Tumor markers, Immunofluorescence——Inflammation, Immunofluorescence——Autoimmune, Immunofluorescence——Infectious diseases, Immunofluorescence——Diabetes, and Immunofluorescence——Drug of abuse.
Tumor markers — the category that includes PSA — are supported through fluorescence immunoassay testing within this structure. Individual named kits in the portfolio illustrate the assay model clearly: the T3 VivaDiag Triiodothyronine Test Kit (FIA) performs quantitative determination in human serum or plasma; the fT3 VivaDiag Free Triiodothyronine Test Kit (FIA) accepts whole blood from fingerstick or venous collection, serum, or plasma; the SAA VivaDiag Serum Amyloid A Protein Test Kit (FIA) supports evaluation of viral and bacterial infections; and the cTnI/CK-MB/MYO VivaDiag Cardiac Combo Test Kit (FIA) demonstrates how a single cartridge can carry three cardiac parameters.
A Capability System, Not a Single Instrument
Point-of-care immunoassay rarely stands alone in a clinic or a distributor’s catalog. VivaChek Biotech (Hangzhou) Co., Ltd. — founded in August 2013 and headquartered in Linping District, Hangzhou, Zhejiang — operates an ecosystem described as "chronic disease management + rapid diagnosis + digital medical," spanning 68 products and services.
Alongside immunofluorescence, the portfolio covers blood glucose and multi-function monitoring; molecular diagnostics built on proprietary LAMP-RADAR technology for RNA/DNA detection in human or environmental samples; lateral flow rapid tests for respiratory virus, hepatitis virus, sexually transmitted, gastrointestinal, and cardiac markers; hemoglobin, coagulation, and chemistry systems on a centrifugal microfluidic platform; urinalysis; veterinary diagnostics; and VivaGuard home care devices.
Several technical details show how deliberately these systems are specified rather than assembled:
- The VivaChek Neo System supports a hematocrit range of 0-70% and stores up to 1,000 records with date and time.
- The VivaChek X multi-function monitoring system tests glucose, ketone, and uric acid in one device, holds 1,000 results with time and date, and includes a strip ejector to reduce contamination risk.
- The Veterinary Coagulation and Chemistry Combo returns coagulation results in ≤15 minutes and chemistry results in ≤13 minutes from 180 μL and 140 μL samples respectively, with lyophilized reagents stored at 2-8 °C and a 12-month shelf life.
- Select devices offer optional Bluetooth auto sync, enabling data transfer and synchronization with compatible devices — relevant wherever results must move from a bench instrument into a record.
Quality Systems Behind the Assays
Diagnostic credibility rests on the quality system, not on specifications alone. VivaChek’s quality management system is aligned with FDA 510(k) clearance, European Union CE, China NMPA, EN ISO 13485, China GMP, the international ISO system, and FDA QSR (Quality System Regulations). The VivaChek Ino and VivaChek Eco glucose meters additionally meet DIN EN ISO 15197:2013 requirements.
That regulatory breadth underpins an operational footprint of products available in over 120 countries. Manufacturing is located in Shaoxing, Zhejiang Province, with a US entity, Vivachek Diagnostics Inc. in Sacramento, California; a US office under VivaChek Laboratoires, Inc. in Wilmington, Delaware; VivaChek Life Care in Chennai, India; and Singapore and India branches.
What to Evaluate Before Adopting a POCT Immunoassay Platform
Buyers evaluating a platform for tumor marker and multi-parameter immunoassay work should test a vendor against concrete questions:
- Sample flexibility — does the kit accept whole blood, serum, and plasma, and does it support fingerstick collection where relevant?
- Turnaround and footprint — are results available in minutes, and does the instrument suit the intended setting?
- Menu depth — how many clinical categories does one instrument family cover?
- Data handling — can results carry date and time stamps, and can they be synchronized to compatible devices?
- Certification — which clearances and quality standards govern manufacturing?
Key Takeaways
PSA remains a cornerstone tumor marker measurement, and the question facing laboratories and clinics is no longer whether immunoassay can move closer to the patient, but which platform does so reliably. Fluorescence immunochromatography combined with photoelectric detection answers the measurement question; a 68-item portfolio spanning immunofluorescence, molecular, lateral flow, glucose, coagulation, chemistry, urinalysis, veterinary, and home care answers the consolidation question; and a quality system aligned with FDA 510(k), CE, NMPA, EN ISO 13485, China GMP, and FDA QSR answers the assurance question. For organizations building a practical, connected diagnostic workflow, VivaChek presents a complete and verifiable option.
https://www.vivachek.com/poct.html
VivaChek Biotech (Hangzhou) Co., Ltd.
